News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,286 Results
Type
Article (43332)
Company Profile (273)
Press Release (669680)
Multimedia
Podcasts (68)
Webinars (14)
Section
Business (205655)
Career Advice (2027)
Deals (35663)
Drug Delivery (97)
Drug Development (82199)
Employer Resources (172)
FDA (16448)
Job Trends (15015)
News (348268)
Policy (32858)
Tag
Academia (2647)
Accelerated approval (11)
Adcomms (24)
Allergies (95)
Alliances (50044)
ALS (118)
Alzheimer's disease (1529)
Antibody-drug conjugate (ADC) (152)
Approvals (16435)
Artificial intelligence (314)
Autoimmune disease (30)
Automation (18)
Bankruptcy (363)
Best Places to Work (11737)
BIOSECURE Act (19)
Biosimilars (121)
Biotechnology (193)
Bladder cancer (93)
Brain cancer (34)
Breast cancer (365)
Cancer (2873)
Cardiovascular disease (212)
Career advice (1692)
Career pathing (30)
CAR-T (189)
CDC (31)
Cell therapy (506)
Cervical cancer (22)
Clinical research (67568)
Collaboration (1030)
Company closure (3)
Compensation (686)
Complete response letters (25)
COVID-19 (2646)
CRISPR (57)
C-suite (328)
Cystic fibrosis (112)
Data (3007)
Decentralized trials (2)
Denatured (20)
Depression (72)
Diabetes (348)
Diagnostics (6449)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (141)
Drug pricing (123)
Drug shortages (28)
Duchenne muscular dystrophy (128)
Earnings (87715)
Editorial (43)
Employer branding (21)
Employer resources (148)
Events (114773)
Executive appointments (851)
FDA (18107)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (948)
Gene editing (131)
Generative AI (22)
Gene therapy (388)
GLP-1 (791)
Government (4534)
Grass and pollen (4)
Guidances (181)
Healthcare (19008)
Huntington's disease (32)
IgA nephropathy (39)
Immunology and inflammation (150)
Immuno-oncology (8)
Indications (39)
Infectious disease (2818)
Inflammatory bowel disease (150)
Inflation Reduction Act (10)
Influenza (64)
Intellectual property (120)
Interviews (316)
IPO (16674)
IRA (44)
Job creations (3672)
Job search strategy (1435)
Kidney cancer (13)
Labor market (52)
Layoffs (497)
Leadership (18)
Legal (7976)
Liver cancer (79)
Lung cancer (402)
Lymphoma (210)
Machine learning (11)
Management (58)
Manufacturing (387)
MASH (91)
Medical device (13673)
Medtech (13678)
Mergers & acquisitions (19706)
Metabolic disorders (855)
Multiple sclerosis (100)
NASH (16)
Neurodegenerative disease (136)
Neuropsychiatric disorders (38)
Neuroscience (2258)
NextGen: Class of 2025 (6593)
Non-profit (4540)
Now hiring (47)
Obesity (431)
Opinion (221)
Ovarian cancer (101)
Pain (112)
Pancreatic cancer (121)
Parkinson's disease (197)
Partnered (22)
Patents (298)
Patient recruitment (163)
Peanut (50)
People (58164)
Pharmaceutical (68)
Pharmacy benefit managers (22)
Phase I (21057)
Phase II (29769)
Phase III (22139)
Pipeline (1639)
Policy (202)
Postmarket research (2607)
Preclinical (9044)
Press Release (64)
Prostate cancer (141)
Psychedelics (38)
Radiopharmaceuticals (256)
Rare diseases (473)
Real estate (5961)
Recruiting (66)
Regulatory (22846)
Reports (50)
Research institute (2404)
Resumes & cover letters (351)
Rett syndrome (10)
RNA editing (9)
RSV (49)
Schizophrenia (92)
Series A (161)
Series B (114)
Service/supplier (11)
Sickle cell disease (60)
Special edition (21)
Spinal muscular atrophy (162)
Sponsored (32)
Startups (3640)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (46)
Vaccines (786)
Venture capital (53)
Weight loss (259)
Women's health (47)
Worklife (16)
Date
Today (66)
Last 7 days (379)
Last 30 days (1893)
Last 365 days (31590)
2025 (16897)
2024 (35585)
2023 (40410)
2022 (51555)
2021 (56102)
2020 (54414)
2019 (46963)
2018 (35381)
2017 (32512)
2016 (31995)
2015 (38010)
2014 (31764)
2013 (26991)
2012 (29094)
2011 (29659)
2010 (27715)
Location
Africa (725)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38708)
Australia (6377)
California (7465)
Canada (2364)
China (677)
Colorado (322)
Connecticut (320)
Delaware (192)
Europe (84264)
Florida (1123)
Georgia (249)
Hawaii (1)
Idaho (59)
Illinois (650)
India (26)
Indiana (362)
Iowa (16)
Japan (228)
Kansas (109)
Kentucky (30)
Louisiana (15)
Maine (64)
Maryland (1021)
Massachusetts (5601)
Michigan (252)
Minnesota (452)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2083)
New Mexico (29)
New York (2100)
North Carolina (1087)
North Dakota (8)
Northern California (3284)
Ohio (236)
Oklahoma (16)
Oregon (34)
Pennsylvania (1617)
Puerto Rico (17)
Rhode Island (36)
South America (1112)
South Carolina (34)
South Dakota (1)
Southern California (2791)
Tennessee (127)
Texas (1123)
United States (27736)
Utah (221)
Virginia (185)
Washington D.C. (75)
Washington State (633)
West Virginia (4)
Wisconsin (67)
713,286 Results for "alzamend neuro inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alzamend Neuro Announces Reverse Stock Split
May 8, 2025
·
4 min read
Press Releases
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
June 16, 2025
·
4 min read
Press Releases
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 14, 2025
·
5 min read
Press Releases
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 29, 2025
·
5 min read
Press Releases
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 19, 2025
·
5 min read
Press Releases
Alzamend Neuro to Present at the Sequire Investor Summit
January 15, 2025
·
3 min read
Press Releases
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
May 8, 2025
·
5 min read
Policy
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
Alzamend Neuro, Inc. announced that the Nasdaq Hearings Panel granted Alzamend’s request to continue its listing on The Nasdaq Capital Market, subject to Alzamend demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550, which requires stockholder equity of at least $2.5 million, and satisfying all applicable requirements for continued listing on Nasdaq.
May 22, 2024
·
3 min read
BioMidwest
Alzamend Neuro Announces Initial Closing of Private Placement
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder, announced that it closed upon the initial tranche of a private placement pursuant to the Securities Purchase Agreement with an institutional investor.
May 14, 2024
·
5 min read
BioMidwest
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
Alzamend Neuro, Inc. announced that it has terminated its “at-the-market” equity offering program relating to sales of common stock with Ascendiant Capital Markets, LLC, as sales agent.
May 7, 2024
·
3 min read
1 of 71,329
Next
